US Edition
Published • loading... • Updated
Blue Cross touts $147M savings with biosimilar drugs
Summary by crainsgrandrapids.com
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
Blue Cross touts $147M savings with biosimilar drugs
Blue Cross Blue Shield of Michigan announced Wednesday that, through the use of drugs that mimic expensive specialty brand-name drugs, it has saved members and employee groups over $147 million between 2024 and 2025. Biosimilars are Food and Drug Administration-approved, highly similar versions of existing, complex biologic medications made from... Please login to read all 566 words.
·Grand Rapids, United States
Read Full ArticleCoverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
